Related resources
Full-text held externally
- PMID: 22422135
- UKPMCID: 22422135
- DOI: 10.1097/MPA.0b013e3182327a03
Search for item elsewhere
University researcher(s)
EGFR and KRAS mutational analysis and their correlation to survival in pancreatic and periampullary cancer.
Oliveira-Cunha, Melissa; Hadfield, Kristen D; Siriwardena, Ajith K; Newman, William
Pancreas. 2012;41(3):428-34.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
- PMID: 22422135
- UKPMCID: 22422135
- DOI: 10.1097/MPA.0b013e3182327a03
Abstract
OBJECTIVES: Pancreatic and periampullary cancers have a high incidence of activating KRAS mutations. The aim of this study was to determine the incidence of KRAS and EGFR mutations in pancreatic and periampullary cancers and their relationship with survival. METHODS: One hundred patients undergoing pancreaticoduodenectomy or pancreatic biopsy for cancer were recruited. Samples of formalin-fixed paraffin-embedded or fresh pancreatic tissue were obtained. EGFR was analyzed by DNA sequencing of exons 18 to 21. KRAS was analyzed by pyrosequencing of codons 12, 13, and 61. RESULTS: EGFR mutations were found in 2 (2.3%) of 88 assessable cases. One in exon 18 (c.1966C>T, p.Q710X) and 1 in exon 19 (c.2066A>G, p.E734G). A synonymous single-nucleotide polymorphism in exon 20 (c.2361G>A, p.Q787) was identified in 57 (67.8%) of 84 patients studied. Twenty-eight (41.2%) of 68 cases harbored a point mutation in KRAS codon 12 (26 cases) and codon 61 (2 cases). The overall median survival was 308 days (range, 7-2623 days). The presence of KRAS point mutations did not significantly alter median survival time (22.8 vs 28.1 months, P = 0.88). CONCLUSIONS: EGFR somatic mutations are rare in pancreatobiliary malignancies. KRAS mutations are less common than previous reports and do not correlate with survival.